Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Altimmune (ALT) over the last 15 years, with Q3 2025 value amounting to $0.08.

  • Altimmune's Debt to Equity changed N/A to $0.08 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.08, marking a year-over-year change of. This contributed to the annual value of $0.02 for FY2022, which is 3474.0% down from last year.
  • Per Altimmune's latest filing, its Debt to Equity stood at $0.08 for Q3 2025.
  • Altimmune's 5-year Debt to Equity high stood at $0.09 for Q2 2025, and its period low was $0.01 during Q2 2021.
  • For the 4-year period, Altimmune's Debt to Equity averaged around $0.03, with its median value being $0.02 (2023).
  • Examining YoY changes over the last 5 years, Altimmune's Debt to Equity showed a top increase of 36799.66% in 2021 and a maximum decrease of 8368.01% in 2021.
  • Over the past 4 years, Altimmune's Debt to Equity (Quarter) stood at $0.04 in 2021, then crashed by 34.74% to $0.02 in 2022, then rose by 15.78% to $0.03 in 2023, then soared by 171.9% to $0.08 in 2025.
  • Its Debt to Equity stands at $0.08 for Q3 2025, versus $0.09 for Q2 2025 and $0.03 for Q3 2023.